Vedere Bio II Revenue and Competitors
Estimated Revenue & Valuation
- Vedere Bio II's estimated annual revenue is currently $1.7M per year.
- Vedere Bio II's estimated revenue per employee is $155,000
Employee Data
- Vedere Bio II has 11 Employees.
- Vedere Bio II grew their employee count by -79% last year.
Vedere Bio II's People
| Name | Title | Email/Phone |
|---|
Vedere Bio II Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Vedere Bio II?
Vedere® is a stealth-stage company developing best-in-class genotype-agnostic gene therapies for vision restoration.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
-79%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vedere Bio II News
2022-04-13 - Vedere Bio II Announces Appointment of Industry Veteran ...
Vedere Bio II Announces Appointment of Industry Veteran Gina Consylman as Chief Financial Officer. (PRNewsfoto/Vedere Bio, Inc.) News provided...
2022-04-13 - Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena ...
Prior to AskBio, Mansell was managing director and founder of White Oak BioPharma ... Vedere Bio II: Gina Consylman was named CFO of Vedere.
2022-04-06 - Belite Bio hits go on IPO to fund late-phase vision loss clinical ...
Belite Bio wants public investors to bankroll late-phase clinical trials of a ... Vedere Bio II has hired Gina Consylman as CFO to chart the financial...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 11 | N/A | N/A |
#2 | $0.9M | 11 | -71% | $138.8M |
#3 | $1.6M | 11 | 10% | N/A |
#4 | $1.7M | 11 | -15% | N/A |
#5 | $1.5M | 11 | -15% | N/A |